| 产品描述: | Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research. |
| 靶点: |
CCR4 |
| 体外研究: |
Zelnecirnon (100 mg/kg;口服;每日一次;连用 2 天,在 OVA 刺激前 1 天服用) 可减轻小鼠急性卵清蛋白 (OVA) 诱发的特应性皮炎模型中的皮肤炎症[2]。 |
| 体内研究: |
Zelnecirnon (1 nM-10 μM) 抑制 Th2 细胞趋化性或迁移,IC50 约为 370 nM。 |
| 参考文献: |
1. Bissonnette R, et al. RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis[C]//EXPERIMENTAL DERMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021, 30: 40-41. 2. Cheng L, et al. Development and first-in-human characterization of a potent oral CCR4 antagonist for the treatment of atopic dermatitis[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2020, 140(7): S77-S77. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.764 ml |
8.819 ml |
17.638 ml |
| 5 mM |
0.353 ml |
1.764 ml |
3.528 ml |
| 10 mM |
0.176 ml |
0.882 ml |
1.764 ml |
| 50 mM |
0.035 ml |
0.176 ml |
0.353 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |